Introduction
============

Health information technology (HIT) has an overall positive impact on healthcare delivery and patient outcomes^[@r1-2380164],[@r2-2380164]^. However, poorly designed and implemented systems can have detrimental effects^[@r3-2380164][@r4-2380164]--[@r5-2380164]^. Many studies have focused on usability of HIT; however, software defects that have high adverse consequences are common in many high-risk fields. Consequently, vigilance in identifying and correcting defects in HIT is essential^[@r6-2380164],[@r7-2380164],[@r8-2380164],[@r9-2380164]^.

ATHENA-HTN is a knowledge-based clinical decision support (CDS) system designed to provide patient-specific recommendations based on guidelines from the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC) and the VA Diagnosis and Management of Hypertension in the Primary Care Setting^[@r10-2380164]^. Originally designed for delivery of recommendations on hypertension (HTN) management as a model, the system has been expanded to ATHENA-CDS, which includes knowledge bases encoding clinical practice guideline (CPG)-based recommendations for chronic kidney disease (CKD), heart failure (HF), diabetes (DM), and hyperlipidemia (HL). We have been reconfiguring the CDS for use within a clinical dashboard rather than within an electronic health record.

With the release of the Eighth Report of the JNC (JNC 8), the ATHENA-CDS-HTN knowledge base (KB) was updated to reflect the new guidelines^[@r11-2380164]^. While the changes to blood pressure targets were relatively easy to encode, the changes to prioritization of drug choices in JNC 8 required re-encoding of the ATHENA-HTN KB. As a result, regression testing, which is software testing used to detect defects from incremental changes to the code, was not suitable, and complete re-evaluation was necessary.

CDS system testing aims to ensure adequate coverage of the knowledge encoded as well as consistency and accuracy of results^[@r12-2380164]^. Unfortunately, software testing is a challenging task that is labor-intensive and expensive. Software engineering studies have found that quality assurance typically accounts for 50-60% of total software development costs^[@r13-2380164],[@r14-2380164],[@r15-2380164],[@r16-2380164]^. Despite the amount of time and money devoted to testing, its effectiveness is lower than expectations, with only 30-60% of defects being found^[@r17-2380164]^.

Software testing is often constrained by limitations in resources, for example, time, labor, and computing power. There is often a trade-off between the testing coverage (amount of the logic tested) and the size of the test suite (number of test cases and testing cycles) utilized^[@r18-2380164]^. Systematic techniques are necessary to make testing effective and efficient. In CDS, testing the accuracy of the system's output requires human evaluation of test cases to establish a reference standard set of test cases with correct output^[@r7-2380164],[@r19-2380164]^. In complex clinical decisions with multiple associated clinical characteristics to consider, the number of possible case scenarios can make it impractical to generate reference standards for each. For example, in HTN management, the presence of chronic comorbid conditions greatly increases the complexity of medication recommendations ([Figure 1](#f1-2380164){ref-type="fig"}) ^[@r20-2380164]^.

With an increased focus on CDS, methods are needed for test case selection that will allow for testing key components of the CDS while keeping the number of cases within the range feasible for establishing the reference standard. There are many methods of testing described in computer science, however there are few publications discussing testing techniques in CDS. In this paper, we explore one approach to test case selection for a complex CDS, using well-studied methods in computer science.

Methods
=======

CDS system to be tested: ATHENA-CDS architecture
------------------------------------------------

The ATHENA-CDS system uses the EON Guideline Interpreter system developed at the Stanford Center for Biomedical Informatics Research (BMIR), including a KB modeled in Protégé, a knowledge acquisition program also developed at BMIR ([Figure 2](#f2-2380164){ref-type="fig"})^[@r21-2380164]^. Clinical data from the electronic health record is available in a relational database. EON processes the clinical data with knowledge in the KB to generate conclusions about the state of the patient and recommendations for next steps in therapy. In the current implementation, ATHENA-CDS's output is designed for display in a clinical dashboard for primary care teams. Testing as described in this paper was conducted in a test environment that mimics the computing environment of the Veterans Integrated Service Network (VISN) 21 Clinical Dashboard, but is populated with completely de-identified patient data.

Hypertension management complexity
----------------------------------

The complexity of the HTN-KB was determined by three methods. The first method programmatically traversed the KB logic and determined the number of clinical decision branch points. The second method counted the total number of data elements (e.g., vitals, labs, medications, comorbidities) referenced by the ATHENA-HTN system. The third method determined of the total number of unique outputs that could be generated by the ATHENA-HTN system as a surrogate for the total number of linear pathways in the logic^[@r18-2380164]^. The total number of outputs from the ATHENA-HTN system was calculated from an analysis of major outputs (recommendations, messages) unique to HTN management. Free-text messages generated to provide supplemental information about recommendations were excluded for this stage of testing. Outputs generated from encodings shared by multiple knowledge bases were excluded (e.g. specific drug-related messages such as drug-drug interactions). Also, combinations of outputs that were not logically possible were excluded.

Knowledge base encoding
-----------------------

Three physicians reviewed the JNC 8 guidelines. During the review, they collaboratively discussed the guideline recommendations and mapped their consensus interpretation into an overview flow diagram ([Figure 3](#f3-2380164){ref-type="fig"}). Eligibility criteria, exclusion criteria, logical flow, and border constraints were also determined. Included in the logic were medications that were directly referenced by the guidelines as well as medications and comorbidities with significant interactions. Laboratory tests were identified by standard LOINCs^[@r22-2380164]^ The KB was then encoded into the Protégé system by a physician knowledge engineer. As part of the encoding process, the knowledge engineer performed unit testing with sample data after each section of the guidelines was encoded, to check that the subset of knowledge just entered processed as intended. This unit testing was done in a test environment that is convenient to use during knowledge encoding; it tests the KB and the guideline interpreter (together these are the EON system), but does not test the larger system architecture that extracts patient data from the relational database and submits it to the EON system. A text-based "Rules" document was created to serve as a reference for how the guidelines were encoded into the knowledge base.

Pre-Pilot Testing
-----------------

When the initial KB encoding and unit testing were complete, pre-pilot tests were performed with patient data from the relational database to verify system integrity and identify major defects in KB encoding. The pre-pilot set was run in a test environment using the EON Guideline Interpreter to generate messages and recommendations from the encoded KB and electronic health record patient data stored in a relational database. Expected outputs for the test patient data were manually determined by two clinical experts. Recommendations from the two clinical experts were compared and modified to create a reference standard. This reference standard was then compared with the ATHENA-HTN output to identify defects.

100 Case Pilot Testing
----------------------

The major objective of the pilot testing phase was to detect errors in order to identify improvements needed to the ATHENA-HTN system to ensure that its recommendations were in accord with guideline-based clinical decisionmaking.

### Test case selection

Analysis of the logical flow diagram of the guidelines was used to partition the test cases into major categories for testing. For each category, clinical characteristics (e.g. blood pressure, comorbidities, presence or absence of medications on active medication list) were determined for use as test case selection criteria. Test cases that met criteria for each test category were then selected randomly from a dataset of 5000 patients seen at VAPAHCS in 2009-2013 that had been fully de-identified prior to use for this study.

### Testing procedure

100 patient cases were selected from the dataset using the criteria outlined above. Guideline-based recommendations were made on the test cases by a physician (MA), who was very familiar with the Rules document and the intended encoding of ATHENA-HTN, and by a pre-clinical medical student (KY) who used the Rules document to guide recommendations. Patient data was presented to these raters with a custom- designed clinical user interface generated in Microsoft Access and populated with data from a SQL Server database. The human testers recorded correct conclusions and recommendations for each case. They both rated 20 cases and resolved any discrepancies. The medical student then completed the remaining 80 cases. The resulting set of 100 test cases with human-generated correct answers constituted the reference standard against which the CDS would be judged. The ATHENA-HTN system processed the 100 cases and the output was stored in the Access database for comparison. Differences between recommendations by the CDS and the reference standard were compiled by the medical student and reviewed with the physician. The development team then analyzed and classified discrepancies between the ATHENA-HTN output and the human reference standard. We report here the extent to which the test cases provided coverage of the logic flow and potential recommendations.

Results
=======

Patient selection characteristics
---------------------------------

With analysis of the encoded guidelines and logic flow, the HTN management algorithm was divided into seven pathways. Six of the pathways had distinct clinical characteristics as inputs into the logic that did not result in drug recommendations. The last pathway included all of the drug recommendations for patients with blood pressure above the target. This pathway was sub-divided into five pathways based on the absence of a preferred antihypertensive drug class in their active medication list. Eighty test cases were selected to meet criteria in one of these 11 major pathways (6 without drug recommendation, 5 with drug recommendation). Another 20 cases who met eligibility requirements were randomly selected from the dataset ([Table 1](#t1-2380164){ref-type="table"}).

Hypertension management complexity
----------------------------------

The updated ATHENA-HTN guidelines were encoded into the KB with 915 Protégé knowledge frames that include information about medication and patient conditions. These knowledge frames referenced another 2166 subclasses of medical information in the knowledge base. The encoded HTN guideline included 26 clinical decision branch points. Thirty-nine drugs or drug classes and 43 patient data elements (clinical characteristics) were referenced in the guideline.

From the analysis of the major outputs generated by the hypertension module, there were five case scenarios that resulted in messages without further drug recommendations. When drug recommendations were made, each drug class could be started (Add), started after some action (Contingent Add), increased in dose (Increase Dosage), increased in dose after some action (Contingent Increase Dosage), or stopped. Considering these outputs and excluding messages not unique to hypertension management, we calculated a total of 3120 possible CDS output combinations.

Testing output
--------------

After processing of the 100 test cases by ATHENA-HTN, all of the eleven major pathways were tested ([Table 2](#t2-2380164){ref-type="table"}). The testing evaluated the rule-in logic for each of the six non-drug recommending pathways and all five pathways recommending one of the preferred drug classes in the HTN guidelines. A total of 31 unique output combinations were generated by the test cases out of the 3120 logically possible combinations. Out of the 3113 possible drug recommendation combinations, only 20 different combinations were generated from the test cases ([Table 3](#t3-2380164){ref-type="table"}).

Discussion
==========

This study underscores the complexity of CDS and the challenges that can be encountered in ensuring quality control. We developed a test case selection strategy with a goal of broad testing around critical logic in the CDS. The strategy utilized a combination approach of well-studied methodologies from software engineering including adaptive random testing generation and model-based testing that are described below. The testing achieved our goal of selecting test cases that traversed all of the major pathways in the HTN algorithm flow diagram. However, in this phase of testing, only a small percentage of the total possible pathways in the logic were tested. Also, many of the test cases were effectively redundant in the logic that they tested. Here we discuss the numerous challenges in effective testing and describe methodologies to improve the testing and test case selection.

Human testing constraints
-------------------------

As is generally the situation for evaluating clinical recommendations, the amount of testing we could perform was constrained by the need for a human to establish a reference standard for each test case. This time-intensive task required a physician to review the clinical characteristics of a new patient and record their recommendations for every possible output that the system could generate. Due to this constraint, we limited this round of testing to only 100 patient cases. As a result, we could ideally test only 3.1% of the 3120 possible unique logic pathways. Unfortunately, this limitation can only be overcome with the addition of more test cases in future rounds of testing. The constraint on the number of test cases emphasized the importance of test case selection. For our initial pre- deployment testing, we chose to test each major logic pathway with multiple cases to ensure that indirectly associated inputs for other pathways did not vary the output in unanticipated ways. For future rounds of testing, selection criteria of test cases can be narrowed further to reduce redundancy and limit the number of cases for decision nodes that have already been well-tested. With the establishment of an optimized library of test cases with reference standards, future regression testing can be performed with fewer resources. Automation of testing, after establishment of reference standards, can also be performed in regression testing and has been to shown clear improvement testing costs and efficiency^[@r13-2380164]^.

Test data limitations
---------------------

The clinical dataset used in this study was large and randomly selected. These characteristics are considered positive attributes for many medical studies. However, for CDS testing, a clinical dataset can have both positive and negative results. Large randomized datasets often have characteristics that are normally distributed.^[@r23-2380164]^ This distribution likely contributed to the selection of test cases that repeat the same essential test. Test case generation, where test cases are altered or manufactured to produce non-normalized data, is one method to improve a clinical dataset. Complete creation of a test case library is also an option and is the most common source of test cases in software engineering. However, methods used to create test cases in non-medical software engineering might require substantial revision for application in medical informatics. Creating medical test cases can be complex because not all possible combinations of clinical data are realistic or physiologically possible. Generating clinically-possible test cases would require extensive programming to ensure that, for example, all laboratory values are chemically-consistent. Testing for improbable cases has its utility, however, detecting highly recurring defects is a higher priority in initial pre- deployment testing.

Test case selection challenges
------------------------------

Even with an effective method for obtaining or creating test cases, determining and testing all of the possible testing scenarios is difficult in complex software. With the limitations imposed on testing a CDS, it is often not possible to test all of the scenarios, and thoughtful test case selection becomes vital in order to reduce testing burden and to increase coverage. Many approaches to test case selection have been described in computer science literature. Three of the more common approaches are random testing, input testing, and control flow testing.

### Random testing

The use of random test sets is commonly utilized. Random testing is simple to execute and can often find unanticipated defects in complex logic. With a large number of test cases, complete testing coverage can be theoretically achieved. However, studies have shown that random inputs have a tendency to test the same logic repeatedly, leaving parts of the software untested^[@r24-2380164][@r25-2380164]--[@r26-2380164]^. Adaptive random testing is an effective enhancement to random testing that improves the testing coverage through application of test selection criteria in repeat testing to cover case scenarios not covered in initial testing. An example of an adaptive random testing approach would be to apply selection criteria to exclude cases already in a test case library. Another example is partitioning test cases into groups and then focusing on poorly tested partitions in subsequent testing^[@r13-2380164]^.

### Input testing

Input testing is an approach that samples a subset of the inputs of a software program. Combinatorial testing is a type of input testing that samples a subset of the inputs of a software program. Test cases are selected from the possible set of input combinations^[@r13-2380164]^. Inputs that are numbers such as serum potassium (K), are considered in the context of ranges (for example: K \< 3.0 mEq/L, 3.0 \< K \< 5.5, K \> 5.5). One major limitation to input testing is that the number of combinations quickly increases as the number and complexity of each input increases. For example, a program that tests a patient with five binary clinical characteristics (e.g. gender, systolic blood pressure \> 140 mmHg, has diabetes, serum potassium \< 5.5 mEq/L, presence of microalbuminuria) would have 2^5^ or 32 possible input combinations to test. A program with seven inputs, each with three possible values, has 3^7^ or 2187 possible input combinations. Software that has complex inputs such as clinical data can have an extremely large number of input combinations. The pairwise method, a modification to combinatorial testing, was developed to reduce the number of input combinations tested while retaining quality of coverage. This method focuses on testing interactions between inputs and reduces the number of tests required by focusing only on pairs of input combinations^[@r27-2380164]^.

### Control flow testing

This method selects test cases that cover sequences from a control flow graph. The symbolic execution method constructs a flow graph of the logic through analysis of the software code. This approach has limits to real world applications as the amount of effort required for the analysis and for the identification of appropriate test cases increases enormously with the complexity of the code^[@r13-2380164],[@r26-2380164]^. Model-based testing is a control flow method that constructs the control flow from an abstraction or model of the logic in a software program^[@r13-2380164],[@r28-2380164]^. Models can be derived from sources such as scenario, state, or process diagrams of the logic. Inputs and outputs are specified for each step in the diagram. Test cases are selected from criteria that cover paths in the diagrams. Due to limitations in testing discussed above, sometimes only a subset of the paths in the model can be tested, and some criteria must be established to determine paths that are most important, likely, or critical.

There are many test selection methodologies including others not discussed in this paper. Each method has its own strengths and limitations and some studies have shown that employing a combination of techniques can improve test case selection^[@r13-2380164],[@r17-2380164],[@r26-2380164]^. Software testing experts suggest that the choice of methodology be individualized for each software project. The complexity and composition of the software and the resources available are two major factors that should be considered when choosing a test case selection strategy^[@r29-2380164]^. In testing ATHENA-HTN, these factors have had a great impact on our testing process.

While most implemented CDS provides clinicians with reminders or alerts, with increasing prevalence of multiple comorbidities and polypharmacy, there has been an interest in the development of sophisticated systems that handle more intricate logic and data^[@r6-2380164],[@r30-2380164]^. As discussed in this paper, testing a complex CDS can be quite challenging. Although CDS systems are designed to supplement clinical decision making, incorrect information can potentially cause harm. Sufficient testing of CDS is required prior to deployment; however, there have been few publications on testing techniques and the determination of sufficient testing in CDS. To our knowledge, there is no authoritative guidance on standards or best practices for quality control in CDS and we hope that this paper will contribute to this topic and lead to further investigation

Conclusion
==========

Test case selection is an important and challenging process in CDS testing. The complexity of the system, identification of major logic pathways, available resources, and the need for a reference standard can have major influences on the extent and type of testing performed. We plan to continue validation and verification of ATHENA- HTN through future rounds of testing and further development of our test selection strategy.
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###### 

Patient Test Selection Group Characteristics.

  Patient Selection Groups                                                                                    \# of Patient Cases
  ----------------------------------------------------------------------------------------------------------- ---------------------
  **Not eligible to be considered for HTN recommendations**                                                   5
  **SBP \>= 220 or DBP \>= 110**                                                                              5
  **Ischemic heart diseases and DBP \< 60**                                                                   5
  **BP above target set by the existing VA clinical dashboard but below BP target set by JNC 8 guidelines**   5
  **BP below target set by the existing VA clinical dashboard and the JNC 8 clinical guideline**              5
  **On 4 or more BP medications**                                                                             5
  **Not on ACEI**                                                                                             10
  **Not on ARB**                                                                                              10
  **Not on thiazide diuretic**                                                                                10
  **Not on dihydropyridine CCB**                                                                              10
  **Not on non-dihydropyridine CCB**                                                                          10
  **Patients eligible for HTN recommendations**                                                               20
  **Total**                                                                                                   **100**

HTN - 'Hypertension, BP - Blood pressure, SBP - Systolic blood pressure, DBP - Diastolic blood pressure, VA - Veteran Affairs, JNC - Joint National Committee, ACEI - Angiotensin converting enzyme inhibitor, ARB - Angiotensin receptor blocker, CCB - Calcium channel blocker

###### 

Testing output coverage from 100 patient cases.

  Testing Coverage                       Total Possible   \# of Tested   Percentage
  -------------------------------------- ---------------- -------------- ------------
  **Major pathways**                     11               11             100%
  **Messages**                           12               12             100%
  **Drug classes evaluated**             5                5              100%
  **Drug classes recommended**           5                5              100%
  **Drug classes increased**             5                2              40%
  **Drug recommendation combinations**   3113             20             0.03%
  **Major output combinations**          3120             31             1.0%

###### 

Unique Drug Recommendation Combinations from 100 Test Cases

                                    Recommendations for Drug Classes                                      
  ---- ---------------------------- ---------------------------------- ----------------- ---------------- ----------------
  1                                                                                                       
  2                                                                                      Add              
  3                                                                    Add               Add              
  4                                                                    Contingent Add    Contingent Add   
  5                                                                    Increase Dosage   Add              Add
  6                                 Contingent Add                                                        
  7                                 Contingent Add                                                        
  8    Add                                                                                                
  9    Add                                                                               Add              
  10   Add                                                             Add               Add              Add
  11   Add                          Add                                                  Add              Add
  12   Add                          Add                                                                   
  13   Add                          Add                                Add               Add              Add
  14   Contingent Add                                                                                     
  15   Contingent Add                                                  Contingent Add                     
  16   Contingent Add                                                  Add               Add              Add
  17   Contingent Add               Contingent Add                                                        
  18   Increase Dosage                                                 Add               Add              
  19   Contingent Increase Dosage                                                        Contingent Add   Contingent Add
  20   Contingent Add                                                  Contingent Add    Contingent Add   Contingent Add

The 20 unique drug recommendation outputs from running ATHENA-HTN on the 100 test cases. ACEI, Angiotensin converting enzyme inhibitor; ARB, Angiotensin receptor blocker; CCB, Calcium channel blocker; DHP, Dihydropyridine; NDHP, Non-dihydropyridine; Add, Consider adding the drug class to the medication regimen; Contingent Add, Recommendation of adding the drug class is contingent on the result of a laboratory test; Increase dosage, Consider increasing the dosage of medication; Contingent Increase Dosage, Recommendation for increase in dosage of the drug class is contingent on the result of a laboratory test;
